positionForPages[29]={page:29,positions:[{w:"Although the class of SGLT2 inhibitors is well ",p:[0.511904,0.419983,0.900284,0.419983,0.900284,0.400783,0.511904,0.400783,0.014555,0.005604,0.005604,0.010079,0.010079,0.010079,0.010079,0.010079,0.006070,0.005604,0.010079,0.008950,0.006068,0.008950,0.005604,0.008950,0.007842,0.007842,0.006070,0.010079,0.006713,0.006074,0.011208,0.014555,0.010470,0.012317,0.010079,0.006070,0.005604,0.010079,0.010079,0.005604,0.010079,0.005604,0.005604,0.010079,0.006713,0.007842,0.006064,0.005604,0.007842,0.006074,0.014555,0.008950,0.005604,0.005604,0.005040]},{w:"known in the areas of HF, CKD, T2D, a therapy ",p:[0.511904,0.437087,0.900286,0.437087,0.900286,0.417887,0.511904,0.417887,0.010079,0.010079,0.010079,0.014555,0.010079,0.004685,0.005604,0.010079,0.004679,0.005604,0.010079,0.008950,0.004677,0.008950,0.006713,0.008950,0.008950,0.007842,0.004677,0.010079,0.006713,0.004683,0.014555,0.009600,0.005040,0.004683,0.013446,0.014555,0.014555,0.005040,0.004324,0.012317,0.010079,0.014555,0.005040,0.004683,0.008950,0.004679,0.005604,0.010079,0.008950,0.006713,0.008950,0.010079,0.010079,0.005040]},{w:"coming to market that also blocks SGLT1 is new. ",p:[0.511904,0.454192,0.900284,0.454192,0.900284,0.434992,0.511904,0.434992,0.008950,0.010079,0.015683,0.005604,0.010079,0.010079,0.003302,0.005604,0.010079,0.003310,0.015683,0.008950,0.006713,0.010079,0.008950,0.005604,0.003306,0.005604,0.010079,0.008950,0.005604,0.003302,0.008950,0.005604,0.007842,0.010079,0.003310,0.010079,0.005604,0.010079,0.008950,0.010079,0.007842,0.003308,0.011208,0.014555,0.010470,0.012317,0.010079,0.003310,0.005604,0.007842,0.003312,0.010079,0.008950,0.013246,0.005040,0.005040]},{w:"This  puts  sotagliflozin  in  direct  competition ",p:[0.511904,0.471296,0.900296,0.471296,0.900296,0.452096,0.511904,0.452096,0.012317,0.010079,0.005604,0.007842,0.005040,0.006227,0.010079,0.010079,0.005604,0.007842,0.005040,0.006231,0.007842,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.006215,0.005604,0.010079,0.005040,0.006227,0.010079,0.005604,0.006713,0.008950,0.008950,0.005604,0.005040,0.006219,0.008950,0.010079,0.015683,0.010079,0.008950,0.005604,0.005604,0.005604,0.005604,0.010079,0.010079,0.005040]},{w:"with  two  SGLT2  inhibitors,  dapagliflozin  and ",p:[0.511904,0.488400,0.900280,0.488400,0.900280,0.469201,0.511904,0.469201,0.014555,0.005604,0.005604,0.010079,0.005040,0.003348,0.005604,0.014555,0.010079,0.005040,0.003350,0.011208,0.014555,0.010470,0.012317,0.010079,0.005040,0.003346,0.005604,0.010079,0.010079,0.005604,0.010079,0.005604,0.005604,0.010079,0.006713,0.007842,0.005040,0.005040,0.003342,0.010079,0.008950,0.010079,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.003334,0.008950,0.010079,0.010079,0.005040]},{w:"empagliflozin,  that  already  have  indications ",p:[0.511904,0.505505,0.900294,0.505505,0.900294,0.486305,0.511904,0.486305,0.008950,0.015683,0.010079,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.005040,0.007787,0.005604,0.010079,0.008950,0.005604,0.005040,0.007795,0.008950,0.005604,0.006713,0.008950,0.008950,0.010067,0.010079,0.005040,0.007805,0.010079,0.008950,0.010079,0.008950,0.005040,0.007801,0.005604,0.010079,0.010079,0.005604,0.008950,0.008950,0.005604,0.005604,0.010079,0.010079,0.007842,0.005040]},{w:"for  preventing  HF  hospitalizations  in  patients ",p:[0.511904,0.522609,0.900290,0.522609,0.900290,0.503409,0.511904,0.503409,0.006713,0.010079,0.006713,0.005040,0.003548,0.010079,0.006713,0.008950,0.010079,0.008950,0.010079,0.005604,0.005604,0.010079,0.010079,0.005040,0.003536,0.014555,0.011208,0.005040,0.003554,0.010079,0.010079,0.007842,0.010079,0.005604,0.005604,0.008950,0.005604,0.005604,0.008950,0.008950,0.005604,0.005604,0.010079,0.010079,0.007842,0.005040,0.003526,0.005604,0.010079,0.005040,0.003544,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.007842,0.005040]},{w:"with  HF  as  well  as  approvals  for  T2D  and ",p:[0.511904,0.539713,0.900280,0.539713,0.900280,0.520514,0.511904,0.520514,0.014555,0.005604,0.005604,0.010079,0.005040,0.005691,0.014555,0.011208,0.005040,0.005699,0.008950,0.007842,0.005040,0.005693,0.014555,0.008950,0.005604,0.005604,0.005040,0.005687,0.008950,0.007842,0.005040,0.005695,0.008950,0.010079,0.010079,0.006713,0.010079,0.010079,0.008950,0.005604,0.007842,0.005040,0.005687,0.006713,0.010079,0.006713,0.005040,0.005330,0.012317,0.010079,0.014555,0.005040,0.005693,0.008950,0.010079,0.010079,0.005040]},{w:"preservation  of  renal  function.",p:[0.511904,0.556818,0.767628,0.556818,0.767628,0.537618,0.511904,0.537618,0.010079,0.006713,0.008950,0.007842,0.008950,0.006713,0.010079,0.008950,0.005604,0.005604,0.010079,0.010079,0.005040,0.003877,0.010079,0.006713,0.005040,0.003887,0.006713,0.008950,0.010079,0.008950,0.005604,0.005040,0.003879,0.006713,0.010079,0.010079,0.008950,0.005604,0.005604,0.010079,0.010079,0.005040]},{w:"References:",p:[0.511904,0.608075,0.626839,0.608075,0.626839,0.585808,0.511904,0.585808,0.015687,0.010442,0.007832,0.010442,0.009149,0.010442,0.013076,0.010442,0.010442,0.009149,0.007832]},{w:"•  Mitchel  L.  Zoler.  FDA  Approves  New ",p:[0.511904,0.631184,0.900270,0.631184,0.900270,0.611984,0.511904,0.611984,0.007056,0.005040,0.010644,0.017921,0.005604,0.005604,0.008950,0.010079,0.008950,0.005604,0.005040,0.010626,0.012317,0.005040,0.005040,0.010640,0.012317,0.010079,0.005604,0.008950,0.005590,0.005040,0.005040,0.010644,0.011208,0.014555,0.013452,0.005040,0.009529,0.014555,0.010079,0.010079,0.006713,0.010079,0.010079,0.008950,0.007842,0.005040,0.010648,0.014555,0.008950,0.014555,0.005040]},{w:"Drug,  Sotagliflozin,  for  Heart  Failure. ",p:[0.511904,0.648288,0.900286,0.648288,0.900286,0.629088,0.511904,0.629088,0.014555,0.006713,0.010079,0.010079,0.005040,0.005040,0.019558,0.011208,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.005040,0.019540,0.006713,0.010079,0.006713,0.005040,0.019554,0.014555,0.008950,0.008950,0.006713,0.005604,0.005040,0.019548,0.011208,0.008950,0.005604,0.005604,0.010079,0.006713,0.008950,0.005040,0.005040]},{w:"Available ",p:[0.511904,0.665392,0.593829,0.665392,0.593829,0.646193,0.511904,0.646193,0.013063,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.008950,0.005040]},{w:"at: ",p:[0.617812,0.665392,0.643011,0.665392,0.643011,0.646193,0.617812,0.646193,0.008950,0.005604,0.005604,0.005040]},{w:"https://www.medscape.com/",p:[0.667006,0.665392,0.895261,0.665392,0.895261,0.646193,0.667006,0.646193,0.010079,0.005604,0.005604,0.010079,0.007842,0.005604,0.005604,0.005604,0.014555,0.014555,0.013242,0.005040,0.015683,0.008950,0.010079,0.007842,0.008950,0.008950,0.010079,0.008950,0.005040,0.008950,0.010079,0.015683,0.005604]},{w:"viewarticle/992518#vp_3.  Published  on  May ",p:[0.511904,0.682497,0.900276,0.682497,0.900276,0.663297,0.511904,0.663297,0.010079,0.005604,0.008950,0.014555,0.008950,0.006713,0.005604,0.005604,0.008950,0.005604,0.008950,0.005604,0.010079,0.010079,0.010079,0.010079,0.010079,0.010079,0.010079,0.010079,0.010079,0.010079,0.010079,0.005040,0.005040,0.006816,0.011208,0.010079,0.010079,0.005604,0.005604,0.007842,0.010079,0.008950,0.010079,0.005040,0.006838,0.010079,0.010079,0.005040,0.006842,0.017921,0.008950,0.010079,0.005040]},{w:"26,  2023.  Accessed  on  May  30,  2023.",p:[0.511904,0.699601,0.865129,0.699601,0.865129,0.680401,0.511904,0.680401,0.010079,0.010079,0.005040,0.005040,0.008293,0.010079,0.010079,0.010079,0.010079,0.005040,0.005040,0.007183,0.014555,0.008950,0.008950,0.008950,0.007842,0.007842,0.008950,0.010079,0.005040,0.008287,0.010079,0.010079,0.005040,0.008295,0.017921,0.008950,0.010079,0.005040,0.008293,0.010079,0.010079,0.005040,0.005040,0.008295,0.010079,0.010079,0.010079,0.010079,0.005040]},{w:"• Allison Inserro. FDA Approves Sotagliflozin, a ",p:[0.511904,0.723440,0.900280,0.723440,0.900280,0.704240,0.511904,0.704240,0.007056,0.002621,0.014555,0.005604,0.005604,0.005604,0.007842,0.010079,0.010079,0.003731,0.006713,0.010079,0.007842,0.008950,0.006713,0.006713,0.010079,0.005040,0.003731,0.011208,0.014555,0.013452,0.002619,0.014555,0.010079,0.010079,0.006713,0.010079,0.010079,0.008950,0.007842,0.003731,0.011208,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.003717,0.008950,0.005040]},{w:"Dual SGLT1/2 Inhibitor, for Full Range of Heart ",p:[0.511904,0.740544,0.900280,0.740544,0.900280,0.721344,0.511904,0.721344,0.014555,0.010079,0.008950,0.005604,0.003713,0.011208,0.014555,0.010466,0.012317,0.010079,0.005604,0.010079,0.003709,0.006713,0.010079,0.010079,0.005604,0.010079,0.005604,0.005604,0.010079,0.005896,0.005040,0.003715,0.006713,0.010079,0.006713,0.003715,0.011208,0.010079,0.005604,0.005604,0.003711,0.013446,0.008950,0.010079,0.010079,0.008950,0.003709,0.010079,0.006713,0.003715,0.014555,0.008950,0.008950,0.006713,0.005604,0.005040]},{w:"Failure.  Available  at:  https://www.ajmc.com/",p:[0.511904,0.757648,0.895261,0.757648,0.895261,0.738449,0.511904,0.738449,0.011208,0.008950,0.005604,0.005604,0.010079,0.006713,0.008950,0.005040,0.005040,0.006292,0.013061,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.008950,0.005040,0.007394,0.008950,0.005604,0.005604,0.005040,0.007402,0.010079,0.005604,0.005604,0.010079,0.007842,0.005604,0.005604,0.005604,0.014555,0.014555,0.013242,0.005040,0.008950,0.005604,0.015683,0.008950,0.005040,0.008950,0.010079,0.015683,0.005604]},{w:"view/fda-sotagliflozin-a-dual-sglt1-2-inhibitor-",p:[0.511904,0.774753,0.895269,0.774753,0.895269,0.755553,0.511904,0.755553,0.010170,0.005691,0.009039,0.014655,0.005693,0.006804,0.010170,0.009037,0.006804,0.007943,0.010170,0.005691,0.009039,0.010170,0.005691,0.005691,0.005655,0.005655,0.010170,0.009037,0.005691,0.010170,0.006804,0.009039,0.006804,0.010170,0.010170,0.009039,0.005691,0.006804,0.007943,0.010180,0.005691,0.005691,0.010170,0.006804,0.010170,0.006804,0.005691,0.010170,0.010170,0.005693,0.010170,0.005691,0.005691,0.010170,0.006400,0.006713]},{w:"for-full-range-of-heart-failure.  Published  on ",p:[0.511904,0.791857,0.900276,0.791857,0.900276,0.772657,0.511904,0.772657,0.006713,0.010079,0.006310,0.006713,0.006713,0.010079,0.005604,0.005604,0.006713,0.006713,0.008950,0.010079,0.010079,0.008950,0.006713,0.010079,0.006713,0.006713,0.010079,0.008950,0.008950,0.006713,0.005604,0.006713,0.006713,0.008950,0.005604,0.005604,0.010079,0.006713,0.008950,0.005040,0.005040,0.014678,0.011208,0.010079,0.010079,0.005604,0.005604,0.007842,0.010079,0.008950,0.010079,0.005040,0.014708,0.010079,0.010079,0.005040]},{w:"May 27, 2023. Accessed on May 30, 2023.",p:[0.511904,0.808961,0.865107,0.808961,0.865107,0.789762,0.511904,0.789762,0.017921,0.008950,0.010079,0.006146,0.010079,0.010079,0.005040,0.006144,0.010079,0.010079,0.010079,0.010079,0.005040,0.005040,0.014555,0.008950,0.008950,0.008950,0.007842,0.007842,0.008950,0.010079,0.006144,0.010079,0.010079,0.006144,0.017921,0.008950,0.010079,0.006146,0.010079,0.010079,0.005040,0.006146,0.010079,0.010079,0.010079,0.010079,0.005040]},{w:"S",p:[0.104762,0.426023,0.120640,0.426023,0.120640,0.398076,0.104762,0.398076,0.015878]},{w:"otagliflozin, a novel and first dual agent that ",p:[0.120645,0.423775,0.493143,0.423775,0.493143,0.404576,0.120645,0.404576,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.006852,0.008950,0.006866,0.010079,0.010079,0.010079,0.008950,0.005604,0.006862,0.008950,0.010079,0.010079,0.006866,0.005604,0.005604,0.006713,0.006572,0.006572,0.006878,0.010079,0.010079,0.008950,0.005604,0.006862,0.008950,0.010079,0.008950,0.010079,0.005604,0.006858,0.005604,0.010079,0.008950,0.005604,0.005040]},{w:"inhibits sodium-glucose cotransporter (SGLT) 1 ",p:[0.104762,0.440880,0.493138,0.440880,0.493138,0.421680,0.104762,0.421680,0.005604,0.010079,0.010079,0.005604,0.010079,0.005604,0.005604,0.007842,0.004189,0.007842,0.010079,0.010079,0.005604,0.010079,0.015683,0.006713,0.010079,0.005604,0.010079,0.008950,0.010079,0.007842,0.008950,0.004189,0.008950,0.010079,0.005604,0.006713,0.008950,0.010079,0.007842,0.010079,0.010079,0.006713,0.005604,0.008950,0.006713,0.004191,0.006713,0.011208,0.014555,0.010468,0.012317,0.006713,0.004195,0.010079,0.005040]},{w:"as well as SGLT2, received marketing approval ",p:[0.104762,0.457984,0.493142,0.457984,0.493142,0.438784,0.104762,0.438784,0.008950,0.007842,0.005145,0.014555,0.008950,0.005604,0.005594,0.005145,0.008950,0.007842,0.005142,0.011208,0.014555,0.010470,0.012317,0.010079,0.005040,0.005140,0.006713,0.008950,0.008950,0.008950,0.005604,0.010079,0.008950,0.010063,0.005145,0.015683,0.008950,0.006713,0.010079,0.008950,0.005604,0.005604,0.010079,0.010079,0.005126,0.008950,0.010079,0.010079,0.006713,0.010079,0.010079,0.008950,0.005604,0.005040]},{w:"from  the  US  Food  and  Drug  Administration ",p:[0.104762,0.475089,0.493144,0.475089,0.493144,0.455889,0.104762,0.455889,0.006713,0.006713,0.010079,0.015683,0.005040,0.005142,0.005604,0.010079,0.008950,0.005040,0.005138,0.014555,0.011208,0.005040,0.005151,0.011208,0.010079,0.010079,0.010079,0.005040,0.005149,0.008950,0.010079,0.010079,0.005040,0.005142,0.014555,0.006713,0.010079,0.010079,0.005040,0.004036,0.014555,0.010079,0.015683,0.005604,0.010079,0.005604,0.006572,0.006572,0.006713,0.008950,0.005604,0.005604,0.010079,0.010079,0.005040]},{w:"(FDA) on May 26, 2023 for reducing the risk ",p:[0.104762,0.492193,0.493136,0.492193,0.493136,0.472993,0.104762,0.472993,0.006713,0.011208,0.014555,0.014555,0.006713,0.007267,0.010079,0.010079,0.007257,0.017921,0.008950,0.010079,0.007257,0.010079,0.010079,0.005040,0.007257,0.010079,0.010079,0.010079,0.010079,0.007257,0.006713,0.010079,0.006713,0.007257,0.006713,0.008950,0.010079,0.010079,0.008950,0.005604,0.010079,0.010079,0.007249,0.005604,0.010079,0.008950,0.007251,0.006713,0.005604,0.007842,0.010079,0.005040]},{w:"for  cardiovascular  death,  hospitalization  for ",p:[0.104762,0.509297,0.493142,0.509297,0.493142,0.490098,0.104762,0.490098,0.006713,0.010079,0.006713,0.005040,0.007814,0.008950,0.008950,0.006713,0.010079,0.005604,0.010079,0.010079,0.008950,0.007842,0.008950,0.010079,0.005604,0.008950,0.006713,0.005040,0.007803,0.010079,0.008950,0.008950,0.005604,0.010079,0.005030,0.005040,0.007814,0.010079,0.010079,0.007842,0.010079,0.005604,0.005604,0.008950,0.005604,0.005604,0.008950,0.008950,0.005604,0.005604,0.010079,0.010079,0.005040,0.007787,0.006713,0.010079,0.006713,0.005040]},{w:"heart  failure  (HF),  and  urgent  HF  visits  in ",p:[0.104762,0.526402,0.493138,0.526402,0.493138,0.507202,0.104762,0.507202,0.010079,0.008950,0.008950,0.006713,0.005604,0.005040,0.006658,0.006713,0.008950,0.005604,0.005604,0.010079,0.006713,0.008950,0.005040,0.006654,0.006713,0.014555,0.011208,0.006713,0.005040,0.005040,0.006673,0.008950,0.010079,0.010079,0.005040,0.006664,0.010079,0.006348,0.010079,0.008950,0.010079,0.005604,0.005040,0.006660,0.014555,0.011208,0.005040,0.006675,0.010079,0.005604,0.007842,0.005604,0.005604,0.007842,0.005040,0.006662,0.005604,0.010079,0.005040]},{w:"patients with HF, and also for preventing these ",p:[0.104762,0.543506,0.493142,0.543506,0.493142,0.524306,0.104762,0.524306,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.007842,0.006114,0.014555,0.005604,0.005604,0.010079,0.006124,0.014555,0.009600,0.005040,0.006126,0.008950,0.010079,0.010079,0.006124,0.008950,0.005604,0.007842,0.010079,0.006124,0.006713,0.010079,0.006713,0.006128,0.010079,0.006713,0.008950,0.010079,0.008950,0.010079,0.005604,0.005604,0.010079,0.010079,0.006114,0.005604,0.010079,0.008950,0.007842,0.008950,0.005040]},{w:"same  events  in  patients  with  type  2  diabetes ",p:[0.104762,0.560610,0.493148,0.560610,0.493148,0.541411,0.104762,0.541411,0.007842,0.008950,0.015683,0.008950,0.005040,0.004292,0.008950,0.010079,0.008950,0.010079,0.005604,0.007842,0.005040,0.004292,0.005604,0.010079,0.005040,0.004294,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.007842,0.005040,0.004284,0.014555,0.005604,0.005604,0.010079,0.005040,0.004294,0.005604,0.010079,0.010079,0.008950,0.005040,0.004292,0.010079,0.005040,0.004298,0.010079,0.005604,0.008950,0.010079,0.008950,0.005604,0.008950,0.007842,0.005040]},{w:"(T2D),  chronic  kidney  disease  (CKD),  and ",p:[0.104762,0.577715,0.493138,0.577715,0.493138,0.558515,0.104762,0.558515,0.006713,0.012317,0.010079,0.014555,0.006713,0.005040,0.005040,0.007814,0.008950,0.010079,0.006713,0.010079,0.010079,0.005604,0.008950,0.005040,0.007801,0.010079,0.005604,0.010079,0.010079,0.008950,0.010079,0.005040,0.007805,0.010079,0.005604,0.007842,0.008950,0.008950,0.007842,0.008950,0.005040,0.007805,0.006713,0.013446,0.014555,0.014555,0.006713,0.005040,0.005040,0.007820,0.008950,0.010079,0.010079,0.005040]},{w:"other  cardiovascular  disease  risk  factors.",p:[0.104762,0.594819,0.452179,0.594819,0.452179,0.575619,0.104762,0.575619,0.010079,0.005604,0.010079,0.008950,0.006713,0.005040,0.004985,0.008950,0.008950,0.006713,0.010079,0.005604,0.010079,0.010079,0.008950,0.007842,0.008950,0.010079,0.005604,0.008950,0.006713,0.005040,0.004975,0.010079,0.005604,0.007842,0.008950,0.008950,0.007842,0.008950,0.005040,0.004985,0.006713,0.005604,0.007842,0.010079,0.005040,0.004993,0.006713,0.008950,0.008950,0.005604,0.010079,0.006713,0.007842,0.005040]},{w:"The approval was based on phase 3 results of ",p:[0.104762,0.618657,0.493136,0.618657,0.493136,0.599458,0.104762,0.599458,0.012317,0.010079,0.008950,0.007326,0.008950,0.010079,0.010079,0.006713,0.010079,0.010079,0.008950,0.005604,0.007326,0.014555,0.008950,0.007842,0.007336,0.010079,0.008950,0.007842,0.008950,0.010079,0.007330,0.010079,0.010079,0.007332,0.010079,0.010079,0.008950,0.007842,0.008950,0.007330,0.010079,0.007332,0.006713,0.008950,0.007842,0.010079,0.005604,0.005604,0.007842,0.007328,0.010079,0.006713,0.005040]},{w:"the  SOLOIST-WHF  trial,  which  randomized ",p:[0.104762,0.635762,0.493150,0.635762,0.493150,0.616562,0.104762,0.616562,0.005604,0.010079,0.008950,0.005040,0.006015,0.011208,0.014555,0.012317,0.014555,0.006713,0.011208,0.010472,0.006713,0.019030,0.014555,0.011208,0.005040,0.006027,0.005604,0.006713,0.005604,0.008950,0.005604,0.005026,0.005040,0.006021,0.014555,0.010079,0.005604,0.008950,0.010079,0.005040,0.006019,0.006713,0.008950,0.010079,0.010079,0.010079,0.015683,0.005604,0.008950,0.008950,0.010079,0.005040]},{w:"1222 patients with T2D who had been recently ",p:[0.104762,0.652866,0.493146,0.652866,0.493146,0.633667,0.104762,0.633667,0.010079,0.010079,0.010079,0.010079,0.005870,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.007842,0.005858,0.014555,0.005604,0.005604,0.010079,0.005503,0.012317,0.010079,0.014555,0.005872,0.014555,0.010079,0.010079,0.005870,0.010079,0.008950,0.010079,0.005868,0.010079,0.008950,0.008950,0.010079,0.005864,0.006713,0.008950,0.008950,0.008950,0.010079,0.005604,0.005604,0.010079,0.005040]},{w:"hospitalized for worsening HF. The first dose of ",p:[0.104762,0.669971,0.493134,0.669971,0.493134,0.650771,0.104762,0.650771,0.010079,0.010079,0.007842,0.010079,0.005604,0.005604,0.008950,0.005604,0.005604,0.008950,0.008950,0.010079,0.004759,0.006713,0.010079,0.006713,0.004778,0.014555,0.010079,0.006713,0.007842,0.008950,0.010079,0.005604,0.010079,0.010079,0.004780,0.014555,0.009600,0.005040,0.004415,0.012317,0.010079,0.008950,0.004772,0.005604,0.005604,0.006713,0.006572,0.006572,0.004790,0.010079,0.010079,0.007842,0.008950,0.004778,0.010079,0.006713,0.005040]},{w:"the drug or placebo was administered just before ",p:[0.104762,0.687075,0.493140,0.687075,0.493140,0.667875,0.104762,0.667875,0.005604,0.010079,0.008950,0.003822,0.010079,0.006713,0.010079,0.010079,0.003828,0.010079,0.006713,0.003828,0.010079,0.005604,0.008950,0.008950,0.008950,0.010079,0.010079,0.003814,0.014555,0.008950,0.007842,0.003832,0.008950,0.010079,0.015683,0.005604,0.010079,0.005604,0.006572,0.006572,0.008950,0.006713,0.008950,0.010079,0.003816,0.005604,0.010079,0.006572,0.006572,0.003830,0.010079,0.008950,0.006713,0.010079,0.006713,0.008950,0.005040]},{w:"or just after hospital discharge, and patients were ",p:[0.104762,0.704179,0.493144,0.704179,0.493144,0.684980,0.104762,0.684980,0.010079,0.006713,0.003439,0.005604,0.010079,0.006572,0.006572,0.003445,0.008950,0.006713,0.005604,0.008950,0.006713,0.003431,0.010079,0.010079,0.007842,0.010079,0.005604,0.005604,0.008950,0.005604,0.003429,0.010079,0.005604,0.007842,0.008950,0.010079,0.008950,0.006342,0.010079,0.008950,0.005040,0.003435,0.008950,0.010079,0.010079,0.003437,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.007842,0.003425,0.014555,0.008950,0.006713,0.008950,0.005040]},{w:"followed for a median of nine months. Results ",p:[0.104762,0.721284,0.493138,0.721284,0.493138,0.702084,0.104762,0.702084,0.006713,0.010079,0.005604,0.005604,0.010079,0.014555,0.008950,0.010079,0.006368,0.006713,0.010079,0.006713,0.006374,0.008950,0.006372,0.015683,0.008950,0.010079,0.005604,0.008950,0.010079,0.006362,0.010079,0.006713,0.006374,0.010079,0.005604,0.010079,0.008950,0.006368,0.015683,0.010079,0.010079,0.005604,0.010079,0.007842,0.005040,0.006370,0.013446,0.008950,0.007842,0.010079,0.005604,0.005604,0.007842,0.005040]},{w:"showed  that  the  rate  of  primary  end  point ",p:[0.104762,0.738388,0.493142,0.738388,0.493142,0.719188,0.104762,0.719188,0.007842,0.010079,0.010079,0.014555,0.008950,0.010079,0.005040,0.007183,0.005604,0.010079,0.008950,0.005604,0.005040,0.007168,0.005604,0.010079,0.008950,0.005040,0.007172,0.006713,0.008950,0.005604,0.008950,0.005040,0.007170,0.010079,0.006713,0.005040,0.007179,0.010079,0.006713,0.005604,0.015683,0.008950,0.006713,0.010079,0.005040,0.007168,0.008950,0.010079,0.010079,0.005040,0.007177,0.010079,0.010079,0.005604,0.010079,0.005604,0.005040]},{w:"events  ware  lower  in  the  sotagliflozin  group ",p:[0.104762,0.755492,0.493142,0.755492,0.493142,0.736293,0.104762,0.736293,0.008950,0.010079,0.008950,0.010079,0.005604,0.007842,0.005040,0.004915,0.014555,0.008950,0.006713,0.008950,0.005040,0.004917,0.005604,0.010079,0.014555,0.008950,0.006713,0.005040,0.004917,0.005604,0.010079,0.005040,0.004919,0.005604,0.010079,0.008950,0.005040,0.004921,0.007842,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.004907,0.010079,0.006713,0.010079,0.010079,0.010079,0.005040]},{w:"than in the placebo group by 33%. In addition, ",p:[0.104762,0.772597,0.493152,0.772597,0.493152,0.753397,0.104762,0.753397,0.005604,0.010079,0.008950,0.010079,0.006064,0.005604,0.010079,0.006070,0.005604,0.010079,0.008950,0.006064,0.010079,0.005604,0.008950,0.008950,0.008950,0.010079,0.010079,0.006058,0.010079,0.006713,0.010079,0.010079,0.010079,0.006070,0.010079,0.010079,0.006070,0.010079,0.010079,0.016792,0.005040,0.006070,0.006713,0.010079,0.006070,0.008950,0.010079,0.010079,0.005604,0.005604,0.005604,0.010079,0.010079,0.005040,0.005040]},{w:"sotagliflozin  lowered  the  cardiovascular  death ",p:[0.104762,0.789701,0.493144,0.789701,0.493144,0.770501,0.104762,0.770501,0.007842,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.003179,0.005604,0.010079,0.014555,0.008950,0.006713,0.008950,0.010079,0.005040,0.003185,0.005604,0.010079,0.008950,0.005040,0.003187,0.008950,0.008950,0.006713,0.010079,0.005604,0.010079,0.010079,0.008950,0.007842,0.008950,0.010079,0.005604,0.008950,0.006713,0.005040,0.003173,0.010079,0.008950,0.008950,0.005604,0.010079,0.005040]},{w:"rate  and  death  rate  from  any  cause  by  16% ",p:[0.104762,0.806806,0.493136,0.806806,0.493136,0.787606,0.104762,0.787606,0.006713,0.008950,0.005604,0.008950,0.005040,0.004949,0.008950,0.010079,0.010079,0.005040,0.004959,0.010079,0.008950,0.008950,0.005594,0.010079,0.005040,0.004959,0.006713,0.008950,0.005604,0.008950,0.005040,0.004949,0.006713,0.006713,0.010079,0.015683,0.005040,0.004955,0.008950,0.010079,0.010079,0.005040,0.004957,0.008950,0.008950,0.010079,0.007842,0.008950,0.005040,0.004951,0.010079,0.010079,0.005040,0.004959,0.010079,0.010079,0.016792,0.005040]},{w:"and  18%,  respectively,  compared  to  placebo. ",p:[0.104762,0.823910,0.493152,0.823910,0.493152,0.804710,0.104762,0.804710,0.008950,0.010079,0.010079,0.005040,0.004606,0.010079,0.010079,0.016792,0.005040,0.005040,0.004608,0.006713,0.008950,0.007842,0.010079,0.008950,0.008950,0.005604,0.005604,0.010079,0.008950,0.005604,0.008751,0.005040,0.005040,0.004610,0.008950,0.010079,0.015683,0.010079,0.008950,0.006713,0.008950,0.010079,0.005040,0.004600,0.005604,0.010079,0.005040,0.004606,0.010079,0.005604,0.008950,0.008950,0.008950,0.010079,0.010079,0.005040,0.005040]},{w:"Some adverse events were more common with ",p:[0.104762,0.841014,0.493144,0.841014,0.493144,0.821815,0.104762,0.821815,0.011208,0.010079,0.015683,0.008950,0.006227,0.008950,0.010079,0.010079,0.008950,0.006713,0.007842,0.008950,0.006231,0.008950,0.010079,0.008950,0.010079,0.005604,0.007842,0.006223,0.014555,0.008950,0.006713,0.008950,0.006231,0.015683,0.010079,0.006713,0.008950,0.006225,0.008950,0.010079,0.015683,0.015683,0.010079,0.010079,0.006221,0.014555,0.005604,0.005604,0.010079,0.005040]},{w:"sotagliflozin  than  with  placebo  (diarrhea  and ",p:[0.104762,0.858119,0.493140,0.858119,0.493140,0.838919,0.104762,0.838919,0.007842,0.010079,0.005604,0.008950,0.010079,0.005604,0.005604,0.005604,0.005604,0.010079,0.008950,0.005604,0.010079,0.005040,0.004665,0.005604,0.010079,0.008950,0.010079,0.005040,0.004671,0.014555,0.005604,0.005604,0.010079,0.005040,0.004675,0.010079,0.005604,0.008950,0.008950,0.008950,0.010079,0.010079,0.005040,0.004669,0.006713,0.010079,0.005604,0.008950,0.006713,0.006713,0.010079,0.008950,0.008950,0.005040,0.004665,0.008950,0.010079,0.010079,0.005040]},{w:"severe  hypoglycemia),  but  the  percentage  of ",p:[0.104762,0.875223,0.493134,0.875223,0.493134,0.856023,0.104762,0.856023,0.007842,0.008950,0.010079,0.008950,0.006713,0.008950,0.005040,0.005241,0.010079,0.010079,0.010079,0.010079,0.010079,0.005604,0.010079,0.008950,0.008950,0.015683,0.005604,0.008950,0.006713,0.005040,0.005040,0.005227,0.010079,0.010079,0.005604,0.005040,0.005243,0.005604,0.010079,0.008950,0.005040,0.005241,0.010079,0.008950,0.006713,0.008950,0.008950,0.010079,0.005604,0.008950,0.010079,0.008950,0.005040,0.005227,0.010079,0.006713,0.005040]},{w:"patients  with  hypotension  and  acute  kidney ",p:[0.104762,0.892327,0.493142,0.892327,0.493142,0.873128,0.104762,0.873128,0.010079,0.008950,0.005604,0.005604,0.008950,0.010079,0.005604,0.007842,0.005040,0.006896,0.014555,0.005604,0.005604,0.010079,0.005040,0.006908,0.010079,0.010079,0.010079,0.010079,0.005604,0.008950,0.010079,0.007842,0.005604,0.010079,0.010079,0.005040,0.006902,0.008950,0.010079,0.010079,0.005040,0.006908,0.008950,0.008950,0.010079,0.005604,0.008950,0.005040,0.006898,0.010079,0.005604,0.010079,0.010079,0.008950,0.010079,0.005040]},{w:"injury was similar for both groups.",p:[0.104762,0.909432,0.398369,0.909432,0.398369,0.890232,0.104762,0.890232,0.005604,0.010079,0.005604,0.010079,0.006713,0.010079,0.007765,0.014555,0.008950,0.007842,0.007775,0.007842,0.005604,0.015683,0.005604,0.005604,0.008950,0.006713,0.007759,0.006713,0.010079,0.006713,0.007771,0.010079,0.010079,0.005604,0.010079,0.007771,0.010079,0.006713,0.010079,0.010079,0.010079,0.007842,0.005040]},{w:"Vol. 1 - Issue 2",p:[0.743337,0.965677,0.857137,0.965677,0.857137,0.947594,0.743337,0.947594,0.011649,0.009239,0.005137,0.004620,0.004620,0.009239,0.004620,0.006153,0.004620,0.007188,0.007188,0.007188,0.010274,0.008205,0.004620,0.009239]},{w:"29",p:[0.864761,0.971012,0.897116,0.971012,0.897116,0.940075,0.864761,0.940075,0.015815,0.016540]},{w:"Trends, insights, and news",p:[0.632387,0.063855,0.896162,0.063855,0.896162,0.040840,0.632387,0.040840,0.013942,0.010014,0.010442,0.013076,0.013076,0.009149,0.005880,0.005880,0.006538,0.013076,0.009149,0.006538,0.011759,0.013076,0.007832,0.009149,0.005880,0.005880,0.011759,0.013076,0.013076,0.005880,0.013076,0.010442,0.016980,0.009149]},{w:"Repurposing of a first dual SGLT 1/2 inhibitor ",p:[0.126984,0.360163,0.871152,0.360163,0.871152,0.323997,0.126984,0.323997,0.026683,0.016409,0.020548,0.020548,0.016409,0.020548,0.018479,0.014377,0.010274,0.020548,0.018479,0.009868,0.018479,0.012307,0.009849,0.018479,0.009846,0.010274,0.010274,0.016409,0.012584,0.012584,0.009838,0.020548,0.020548,0.018479,0.010274,0.009853,0.020548,0.028753,0.021258,0.023982,0.009849,0.018479,0.010274,0.018479,0.009846,0.010274,0.020548,0.020548,0.010274,0.020548,0.010274,0.012307,0.018479,0.016409,0.009239]},{w:"with a granted marketing approval",p:[0.126984,0.386295,0.683940,0.386295,0.683940,0.350129,0.126984,0.350129,0.026683,0.010274,0.012307,0.020548,0.010052,0.018479,0.010052,0.018479,0.016409,0.018479,0.020548,0.012307,0.016409,0.020548,0.010052,0.030786,0.018479,0.016409,0.020548,0.016409,0.012307,0.010274,0.020548,0.018479,0.010052,0.018479,0.020548,0.020548,0.015748,0.018479,0.018479,0.018479,0.010274]}]};